Breast Cancer Research and Treatment

, Volume 122, Issue 1, pp 251–257 | Cite as

Current evidence on the relationship between polymorphisms in the COX-2 gene and breast cancer risk: a meta-analysis

  • Ke-Da Yu
  • Ao-Xiang Chen
  • Chen Yang
  • Li-Xin Qiu
  • Lei Fan
  • Wen-Huan Xu
  • Zhi-Ming Shao


The association between single-nucleotide polymorphisms (SNPs) in the COX-2 gene and breast cancer risk is still ambiguous. We here try to derive a more precise estimation of the relationship by performing a meta-analysis based on currently available evidence from literature. More than 15 SNPs have been studied, and the most studied genetic variants were rs5275, rs5277, and rs20417. Crude odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of association between each polymorphism and breast cancer risk under the codominant model, dominant model, and recessive model, respectively (nine studies with 6,968 cases and 9,126 controls for rs5275; three studies with 2,901 cases and 3,463 controls for rs20417; two studies with 5,551 cases and 6,208 controls for rs5277). No overall significant associations were observed in single-locus analysis between the three polymorphisms of COX-2 and breast cancer risk, though a borderline significant increased risk of breast cancer was detected with rs5277 in a recessive model (OR: 1.217, 95% CI: 0.958–1.547, P = 0.107). The results were not changed when studies were stratified by ethnicity. In conclusion, the present meta-analysis suggests that none of the most studied three SNPs (rs5275, rs20417, and rs5277) in the COX-2 gene is a conspicuous low-penetrant risk factor for developing breast cancer. There is a need for further large studies into the role of these polymorphisms (especially rs5277) and other potentially functional polymorphisms/haplotypes in the COX-2 gene as breast cancer risk modifiers.


COX-2 Polymorphism Breast cancer Susceptibility Meta-analysis 



This research is supported by grants from the National Basic Research Program of China (2006CB910501) and the National Natural Science Foundation of China (30971143, 30972936).


  1. 1.
    Pharoah PD, Antoniou AC, Easton DF, Ponder BA (2008) Polygenes, risk prediction, and targeted prevention of breast cancer. N Engl J Med 358:2796–2803CrossRefPubMedGoogle Scholar
  2. 2.
    Easton DF, Eeles RA (2008) Genome-wide association studies in cancer. Hum Mol Genet 17:R109–R115CrossRefPubMedGoogle Scholar
  3. 3.
    Zheng W, Long J, Gao YT, Li C, Zheng Y, Xiang YB, Wen W, Levy S, Deming SL, Haines JL, Gu K, Fair AM, Cai Q, Lu W, Shu XO (2009) Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1. Nat Genet 41:324–328CrossRefPubMedGoogle Scholar
  4. 4.
    Dong LM, Potter JD, White E, Ulrich CM, Cardon LR, Peters U (2008) Genetic susceptibility to cancer: the role of polymorphisms in candidate genes. JAMA 299:2423–2436CrossRefPubMedGoogle Scholar
  5. 5.
    Romano M, Claria J (2003) Cyclooxygenase-2 and 5-lipoxygenase converging functions on cell proliferation and tumor angiogenesis: implications for cancer therapy. FASEB J 17:1986–1995CrossRefPubMedGoogle Scholar
  6. 6.
    Baron JA, Sandler RS (2000) Nonsteroidal anti-inflammatory drugs and cancer prevention. Annu Rev Med 51:511–523CrossRefPubMedGoogle Scholar
  7. 7.
    Moorman PG, Grubber JM, Millikan RC, Newman B (2003) Association between non-steroidal anti-inflammatory drugs (NSAIDs) and invasive breast cancer and carcinoma in situ of the breast. Cancer Causes Control 14:915–922CrossRefPubMedGoogle Scholar
  8. 8.
    Moorman PG, Sesay J, Nwosu V, Kane JG, de Cotret AR, Worley K, Millikan R (2005) Cyclooxygenase 2 polymorphism (Val511Ala), nonsteroidal anti-inflammatory drug use and breast cancer in African American women. Cancer Epidemiol Biomark Prev 14:3013–3014CrossRefGoogle Scholar
  9. 9.
    Half E, Tang XM, Gwyn K, Sahin A, Wathen K, Sinicrope FA (2002) Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res 62:1676–1681PubMedGoogle Scholar
  10. 10.
    Wang SC, Lien HC, Xia W, Chen IF, Lo HW, Wang Z, Ali-Seyed M, Lee DF, Bartholomeusz G, Ou-Yang F, Giri DK, Hung MC (2004) Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. Cancer Cell 6:251–261CrossRefPubMedGoogle Scholar
  11. 11.
    Subbaramaiah K, Norton L, Gerald W, Dannenberg AJ (2002) Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. J Biol Chem 277:18649–18657CrossRefPubMedGoogle Scholar
  12. 12.
    Howe LR, Chang SH, Tolle KC, Dillon R, Young LJ, Cardiff RD, Newman RA, Yang P, Thaler HT, Muller WJ, Hudis C, Brown AM, Hla T, Subbaramaiah K, Dannenberg AJ (2005) HER2/neu-induced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice. Cancer Res 65:10113–10119CrossRefPubMedGoogle Scholar
  13. 13.
    Papafili A, Hill MR, Brull DJ, McAnulty RJ, Marshall RP, Humphries SE, Laurent GJ (2002) Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. Arterioscler Thromb Vasc Biol 22:1631–1636CrossRefPubMedGoogle Scholar
  14. 14.
    Szczeklik W, Sanak M, Szczeklik A (2004) Functional effects and gender association of COX-2 gene polymorphism G-765C in bronchial asthma. J Allergy Clin Immunol 114:248–253CrossRefPubMedGoogle Scholar
  15. 15.
    Zhang X, Miao X, Tan W, Ning B, Liu Z, Hong Y, Song W, Guo Y, Zhang X, Shen Y, Qiang B, Kadlubar FF, Lin D (2005) Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer. Gastroenterology 129:565–576PubMedGoogle Scholar
  16. 16.
    Zhu W, Wei BB, Shan X, Liu P (2009) -765G>C and 8473T>C polymorphisms of COX-2 and cancer risk: a meta-analysis based on 33 case-control studies. Mol Biol Rep. doi: 10.1007/s11033-009-9685-1 Google Scholar
  17. 17.
    Langsenlehner U, Yazdani-Biuki B, Eder T, Renner W, Wascher TC, Paulweber B, Weitzer W, Samonigg H, Krippl P (2006) The cyclooxygenase-2 (PTGS2) 8473T>C polymorphism is associated with breast cancer risk. Clin Cancer Res 12:1392–1394CrossRefPubMedGoogle Scholar
  18. 18.
    Vogel U, Christensen J, Nexo BA, Wallin H, Friis S, Tjonneland A (2007) Peroxisome proliferator-activated receptor-gamma2 Pro12Ala, interaction with alcohol intake and NSAID use, in relation to risk of breast cancer in a prospective study of Danes. Carcinogenesis 28:427–434CrossRefPubMedGoogle Scholar
  19. 19.
    Abraham JE, Harrington P, Driver KE, Tyrer J, Easton DF, Dunning AM, Pharoah PD (2009) Common polymorphisms in the prostaglandin pathway genes and their association with breast cancer susceptibility and survival. Clin Cancer Res 15:2181–2191CrossRefPubMedGoogle Scholar
  20. 20.
    Qiu LX, Chen B, Mao C, Zhan P, Yuan H, Xue K, Li J, Hu XC (2009) STK15 F31I polymorphism is associated with breast cancer risk: a meta-analysis involving 25, 014 subjects. Breast Cancer Res Treat 118:599–603CrossRefGoogle Scholar
  21. 21.
    Yu KD, Di GH, Fan L, Wu J, Hu Z, Shen ZZ, Huang W, Shao ZM (2009) A functional polymorphism in the promoter region of GSTM1 implies a complex role for GSTM1 in breast cancer. FASEB J 23:2274–2287CrossRefPubMedGoogle Scholar
  22. 22.
    Cox DG, Buring J, Hankinson SE, Hunter DJ (2007) A polymorphism in the 3’ untranslated region of the gene encoding prostaglandin endoperoxide synthase 2 is not associated with an increase in breast cancer risk: a nested case-control study. Breast Cancer Res 9:R3CrossRefPubMedGoogle Scholar
  23. 23.
    Gallicchio L, McSorley MA, Newschaffer CJ, Thuita LW, Huang HY, Hoffman SC, Helzlsouer KJ (2006) Nonsteroidal antiinflammatory drugs, cyclooxygenase polymorphisms, and the risk of developing breast carcinoma among women with benign breast disease. Cancer 106:1443–1452CrossRefPubMedGoogle Scholar
  24. 24.
    Gao J, Ke Q, Ma HX, Wang Y, Zhou Y, Hu ZB, Zhai XJ, Wang XC, Qing JW, Chen WS, Jin GF, Liu JY, Tan YF, Wang XR, Shen HB (2007) Functional polymorphisms in the cyclooxygenase 2 (COX-2) gene and risk of breast cancer in a Chinese population. J Toxicol Environ Health A 70:908–915CrossRefPubMedGoogle Scholar
  25. 25.
    Kang S, Kim YB, Kim MH, Yoon KS, Kim JW, Park NH, Song YS, Kang D, Yoo KY, Kang SB, Lee HP (2005) Polymorphism in the nuclear factor kappa-B binding promoter region of cyclooxygenase-2 is associated with an increased risk of bladder cancer. Cancer Lett 217:11–16CrossRefPubMedGoogle Scholar
  26. 26.
    Li F, Ren GS, Li HY, Wang XY, Chen L, Li J (2009) A novel single nucleotide polymorphism of the cyclooxygenase-2 gene associated with breast cancer. Clin Oncol (R Coll Radiol) 21:302–305Google Scholar
  27. 27.
    Shen J, Gammon MD, Terry MB, Teitelbaum SL, Neugut AI, Santella RM (2006) Genetic polymorphisms in the cyclooxygenase-2 gene, use of nonsteroidal anti-inflammatory drugs, and breast cancer risk. Breast Cancer Res 8:R71CrossRefPubMedGoogle Scholar
  28. 28.
    Hartmann LC, Sellers TA, Frost MH, Lingle WL, Degnim AC, Ghosh K, Vierkant RA, Maloney SD, Pankratz VS, Hillman DW, Suman VJ, Johnson J, Blake C, Tlsty T, Vachon CM, Melton LJ 3rd, Visscher DW (2005) Benign breast disease and the risk of breast cancer. N Engl J Med 353:229–237CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2009

Authors and Affiliations

  • Ke-Da Yu
    • 1
    • 2
  • Ao-Xiang Chen
    • 1
    • 2
  • Chen Yang
    • 1
    • 2
  • Li-Xin Qiu
    • 1
    • 3
  • Lei Fan
    • 1
    • 2
  • Wen-Huan Xu
    • 1
    • 2
  • Zhi-Ming Shao
    • 1
    • 2
    • 4
  1. 1.Department of Oncology, Shanghai Medical CollegeFudan UniversityShanghaiPeople’s Republic of China
  2. 2.Department of Breast SurgeryCancer Hospital/Cancer Institute, Breast Cancer Institute, Fudan UniversityShanghaiPeople’s Republic of China
  3. 3.Department of Medical Oncology, Cancer HospitalFudan UniversityShanghaiPeople’s Republic of China
  4. 4.Institutes of Biomedical ScienceFudan UniversityShanghaiPeople’s Republic of China

Personalised recommendations